HZNP Horizon Therapeutics Public Limited Company

107.51
+7.75  (+8%)
Previous Close 99.76
Open 108.64
52 Week Low 60.82
52 Week High 111.33
Market Cap $24,164,866,918
Shares 224,768,551
Float 217,815,003
Enterprise Value $24,226,549,471
Volume 4,238,777
Av. Daily Volume 1,648,573
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
Krystexxa with Methotrexate - MIRROR RCT
Gout
Phase 3
Phase 3
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
HZN-1116
Autoimmune Diseases
Phase 1
Phase 1
Phase 1 trial initiated July 2021.
UPLIZNA - Inebilizumab
Kidney transplant desensitization
Phase 2
Phase 2
Phase 2 enrolment underway.
HZN-4920
Sjögren’s syndrome
Phase 2b
Phase 2b
Phase 2b trial ongoing.
HZN-4920
Rheumatoid Arthritis
Phase 2
Phase 2
Phase 2 trial ongoing.
HZN-4920
Kidney transplant rejection
Phase 2
Phase 2
Phase 2a trial ongoing as of August 2021.
HZN-825
Diffuse cutaneous systemic sclerosis
Phase 2b
Phase 2b
Phase 2b trial to be initiated 3Q 2021.
HZN-825
Idiopathic pulmonary fibrosis (IPF)
Phase 2b
Phase 2b
Phase 2b trial to be initiated 3Q 2021.
HZN-7734
Systemic Lupus Erythematosus
Phase 2
Phase 2
Phase 2 trial initiation of dosing announced June 29, 2021.
HZN-7734
COVID-19-Related Acute Lung Injury
Phase 1b
Phase 1b
Phase 1b trial ongoing.
TEPEZZA (Teprotumumab)
Thyroid Eye Disease (TED)
Approved
Approved
FDA Approval announced January 21, 2020.
TEPEZZA (Teprotumumab)
Thyroid Eye Disease (TED) - chronic
Phase 3
Phase 3
Phase 4 trial to commence mid-2021.
UPLIZNA - Inebilizumab
Myasthenia gravis
Phase 3
Phase 3
Phase 3 trial initiated 4Q 2020.
UPLIZNA - Inebilizumab
IgG4-related disease
Phase 2b
Phase 2b
Phase 2b trial initiated 4Q 2020.
UPLIZNA - Inebilizumab
Neuromyelitis Optica Spectrum Disorder
Approved
Approved
FDA Approval announced June 11, 2020.
ACTIMMUNE
Friedreich's Ataxia (FA)
Phase 3
Phase 3
Phase 3 data released December 8, 2016 - primary endpoint not met.

Latest News

  1. Horizon Therapeutics plc (NASDAQ:HZNP) today announced that it has been named to the 2021 Fortune Best Workplaces for Millennials™ list for the second consecutive year. Horizon ranked 16th out of 100 large companies.

    "We are proud that Fortune has recognized our millennial colleagues who now make up 35% of our workforce and contribute daily to the success of our company," said Tim Walbert, chairman, president and chief executive officer, Horizon. "At Horizon, we go to great lengths to ensure we are exceeding expectations for our millennial employees, offering comprehensive benefit packages that support mental health and work/life balance while providing extensive opportunities for community involvement and career development."

    In addition…

    Horizon Therapeutics plc (NASDAQ:HZNP) today announced that it has been named to the 2021 Fortune Best Workplaces for Millennials™ list for the second consecutive year. Horizon ranked 16th out of 100 large companies.

    "We are proud that Fortune has recognized our millennial colleagues who now make up 35% of our workforce and contribute daily to the success of our company," said Tim Walbert, chairman, president and chief executive officer, Horizon. "At Horizon, we go to great lengths to ensure we are exceeding expectations for our millennial employees, offering comprehensive benefit packages that support mental health and work/life balance while providing extensive opportunities for community involvement and career development."

    In addition to Horizon's best-in-class health, dental and vision insurance, the company provides additional benefits focused on employee well-being, including programs such as where employees receive free access to subsidized backup care days for both children and adults, as well as senior care planning. Additionally, employees have access to pet protection insurance and legal insurance, which covers a wide range of attorney expenses, including home buying or selling, estate planning, adoption assistance. Horizon also provides free all-access memberships to the mindfulness and meditation app, Headspace.

    To determine The Fortune Best Workplaces for Millennials list, Great Place to Work conducted an anonymous survey of nearly 5.3 million employees at Great Place to Work- Certified™ organizations replying to questions describing the extent to which their organization creates a Great Place to Work For All™. A portion of the evaluation was based on what millennials say about how their company works to create a great employee experience that cuts across race, gender, age and disability status to promote an inclusive community no matter who they are or what they do.

    About Horizon

    Horizon is focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, please visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.

    About the Best Workplaces for Millennials

    Great Place to Work® selected the Best Workplaces for Millennials™ by gathering and analyzing confidential survey responses from more than 5.3 million employees at Great Place to Work- Certified™ organizations. To learn more about Great Place to Work certification and recognition on Best Workplaces lists published with Fortune, visit Greatplacetowork.com.

    View Full Article Hide Full Article
  2. Horizon Therapeutics plc (NASDAQ:HZNP) announced today that its second-quarter 2021 financial results will be released on Wednesday, Aug. 4, 2021. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results.

    The live webcast and a replay may be accessed at http://ir.horizontherapeutics.com. Please connect to the Company's website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. A replay of the webcast will be available approximately two hours after the live webcast.

    About Horizon

    Horizon is focused on the discovery, development and commercialization of medicines…

    Horizon Therapeutics plc (NASDAQ:HZNP) announced today that its second-quarter 2021 financial results will be released on Wednesday, Aug. 4, 2021. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results.

    The live webcast and a replay may be accessed at http://ir.horizontherapeutics.com. Please connect to the Company's website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. A replay of the webcast will be available approximately two hours after the live webcast.

    About Horizon

    Horizon is focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, please visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.

    View Full Article Hide Full Article
  3. The Chicago Chapter of the National Investor Relations Institute (NIRI Chicago) has elected 13 officers and directors to its board for the 2021-2022 term, effective July 1.

    "NIRI Chicago has been a critical resource for our members during the COVID-19 pandemic, hosting 15 virtual events that have enabled us to collectively navigate unprecedented challenges in investor relations," said Mike Steele, incoming chapter president. "We are focused on continuing to elevate the member experience by offering unique opportunities to develop professional skills, share best practices and stay abreast of current trends, all while connecting with peers in a cordial environment. We look forward to kicking off a new program year of compelling events, which…

    The Chicago Chapter of the National Investor Relations Institute (NIRI Chicago) has elected 13 officers and directors to its board for the 2021-2022 term, effective July 1.

    "NIRI Chicago has been a critical resource for our members during the COVID-19 pandemic, hosting 15 virtual events that have enabled us to collectively navigate unprecedented challenges in investor relations," said Mike Steele, incoming chapter president. "We are focused on continuing to elevate the member experience by offering unique opportunities to develop professional skills, share best practices and stay abreast of current trends, all while connecting with peers in a cordial environment. We look forward to kicking off a new program year of compelling events, which includes a full-day IR Workshop for professionals of all experience levels on Friday, Sept. 24 at the Metropolitan Club."

    NIRI Chicago Chapter board members for 2021-2022:

    Officers

    President: Michael A. Steele, CFA, IRC, vice president of investor relations, Zebra Technologies Corp. (NASDAQ:ZBRA). Steele most recently served as NIRI Chicago's executive vice president and has been a speaker at NIRI's annual conference and NIRI Chicago events.

    Executive Vice President: Heather Anne Kos, CPA, IRC, vice president of investor relations and communications, Univar Solutions (NYSE:UNVR). Kos is a past member of NIRI's Certification Council and former chair of the IR roundtable of the Manufacturers Alliance for Productivity and Innovation (MAPI).

    Vice President, Programs: Barbara Noverini, CFA, director of investor relations, Morningstar, Inc. (NASDAQ:MORN). This is Noverini's second year on the NIRI Chicago board. She will continue to serve as the chapter's advocacy ambassador.

    Vice President, Communications: Maryellen T. Thielen, APR, ABC, president, Forest Glen Communications LLC. Thielen earlier was a NIRI Chicago chairman, president and executive vice president.

    Vice President, Membership: Jeremy Cohen, senior vice president, investor relations and financial communications, Edelman. This is Cohen's second year on the NIRI Chicago board. He has served on the IR Workshop committee and was named a NIRI 40 Under 40 honoree in 2019.

    Vice President, Treasurer: Martin A. Jarosick, CFA, IRC, vice president of investor relations, CF Industries Holdings, Inc. (NYSE:CF). This is Jarosick's third year on the NIRI Chicago board. He previously served on the NIRI Atlanta board and 2019 NIRI annual conference committee.

    Vice President, Sponsorship: Christine J. Hanneman, senior director of investor relations, ACCO Brands (NYSE:ACCO). Hanneman has managed the chapter's sponsorship program since 2012 and previously was the chapter's vice president, treasurer.

    Directors

    Chairman: Victor J. Jendras, manager of sales, U.S., Q4 Inc. Jendras previously served as NIRI Chicago's president, executive vice president, vice president of programs and IR Workshop committee member.

    Shawn Alcaraz, IRC, director, investor relations, Adtalem Global Education (NYSE:ATGE). This is Alcaraz's first year on the NIRI Chicago board. He is co-chair of the 2021 IR Workshop and has chaired or volunteered on the IR Workshop committee in previous years.

    Terri Anne Powers, IRC, vice president of investor relations and corporate communications, CytoSorbents Corp. (NASDAQ:CTSO). Powers previously was NIRI Chicago's chairman, president, vice president of programs, IR Workshop and NIRI annual conference committee member.

    Rainey Wagner, investor relations financial analyst, Caterpillar Inc. (NYSE:CAT). This is Wagner's first year on the board. She currently is co-chair of the 2021 IR Workshop and has volunteered on the IR Workshop committee in previous years.

    Ruth E. Venning, IRC, executive director, investor relations, Horizon Therapeutics plc (NASDAQ:HZNP). Venning has served in every NIRI Chicago leadership position, most recently as treasurer. She currently is chair of the NIRI national board, a NIRI Senior Roundtable member and a former NIRI annual conference committee member.

    Heather J. Wietzel, IRC, vice president of investor relations and enterprise communications, Horace Mann (NYSE:HMN). This is Wietzel's third year on the NIRI Chicago board. She earlier served as president of the NIRI Cincinnati Tri-State chapter.

    NIRI National Recognition

    Shep Dunlap, vice president of investor relations, Mondelēz International (NASDAQ:MDLZ), was named to the 2021 NIRI Fellows class in April in recognition of his leadership, integrity, involvement and contributions to the investor relations profession. Dunlap previously served on both the NIRI Chicago and NIRI national boards.

    Departing Board Members

    NIRI Chicago extends its gratitude to departing board members:

    • Elizabeth R. Allen, CFA, staff director, investor relations, FedEx Corp. (NYSE:FDX)
    • Shep Dunlap, vice president of investor relations, Mondelēz International (NASDAQ:MDLZ)
    • Victoria Sivrais, founding partner, Clermont Partners and chair-elect, NIRI national board

    The Chicago chapter of the National Investor Relations Institute (NIRI Chicago) provides professional development and networking opportunities to practitioners of investor relations, a strategic management responsibility that integrates finance, communication, marketing and securities law compliance. Through its collaborative community, NIRI advances engagement in the capital markets and drives best practices in corporate disclosures, governance and informed investing. For more information, visit www.niri-chicago.org.

    View Full Article Hide Full Article
  4. Horizon Therapeutics plc (NASDAQ:HZNP) today announced that it will host a virtual R&D Day for investors and analysts on Wednesday, Sept. 29, 2021 at 8 a.m. CT. Horizon's R&D Day will include presentations from the Company's R&D leadership team and key opinion leaders with a focus on the Company's pipeline.

    Additional details, including how to access the live webcast, will follow closer to the event. A recorded archived version of the webcast will be available on Horizon's website shortly after the event.

    About Horizon

    Horizon is focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: we apply…

    Horizon Therapeutics plc (NASDAQ:HZNP) today announced that it will host a virtual R&D Day for investors and analysts on Wednesday, Sept. 29, 2021 at 8 a.m. CT. Horizon's R&D Day will include presentations from the Company's R&D leadership team and key opinion leaders with a focus on the Company's pipeline.

    Additional details, including how to access the live webcast, will follow closer to the event. A recorded archived version of the webcast will be available on Horizon's website shortly after the event.

    About Horizon

    Horizon is focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, please visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.

    View Full Article Hide Full Article
  5. Horizon Therapeutics plc (NASDAQ:HZNP) today announced the first patient has enrolled in a Phase 2 trial to evaluate its development-stage medicine HZN-7734 (formerly VIB7734), a first-in-class, fully human monoclonal antibody targeting immunoglobulin-like transcript 7 (ILT7), to treat people with moderate to severely active systemic lupus erythematosus (SLE). SLE, which accounts for 70 percent of lupus cases1, is an autoimmune disease in which the immune system mistakenly attacks healthy cells and tissues. The Lupus Foundation of America estimates at least 5 million people worldwide are living with a form of lupus, 90 percent of whom are women.2,3

    "Systemic lupus erythematosus has many manifestations, its severity can negatively impact a patient's…

    Horizon Therapeutics plc (NASDAQ:HZNP) today announced the first patient has enrolled in a Phase 2 trial to evaluate its development-stage medicine HZN-7734 (formerly VIB7734), a first-in-class, fully human monoclonal antibody targeting immunoglobulin-like transcript 7 (ILT7), to treat people with moderate to severely active systemic lupus erythematosus (SLE). SLE, which accounts for 70 percent of lupus cases1, is an autoimmune disease in which the immune system mistakenly attacks healthy cells and tissues. The Lupus Foundation of America estimates at least 5 million people worldwide are living with a form of lupus, 90 percent of whom are women.2,3

    "Systemic lupus erythematosus has many manifestations, its severity can negatively impact a patient's quality of life and there are limited treatment options," said Victoria Werth, MD, professor of medicine at the Perelman School of Medicine at the University of Pennsylvania and chief of dermatology at the Corporal Michael J. Crescenz Veteran's Administration Medical Center. "This trial will help determine the safety and efficacy of Horizon's ILT7 antagonist in reducing overall disease activity for patients who live with moderate to severely active SLE."

    The initiation of the Phase 2 trial follows encouraging efficacy and safety data from a Phase 1b trial in patients with cutaneous lupus erythematosus, a form of lupus affecting the skin.4 The Phase 1b study showed HZN-7734 decreased plasmacytoid dendritic cells (pDCs) and reduced Type 1 Interferon both in circulation, as well as the skin of people with cutaneous lupus, demonstrating that this molecule has activity in specific tissues where the disease occurs. HZN-7734 also improved Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity (CLASI-A) scores, a clinical measure of cutaneous lupus, versus placebo.

    The composite primary endpoint of the Phase 2 trial is change in the British Isles Lupus Assessment Group (BILAG)-based Combined Lupus Assessment (BICLA) and reduction in oral glucocorticoid dose after 48 weeks. BICLA is a composite measure of overall SLE disease activity. Additional trial endpoints include other measures of both lupus disease activity and oral glucocorticoid reduction.

    "Research suggests pDCs, a type of immune cell that produces Type 1 Interferon and causes inflammation, play a critical role in the pathogenesis of lupus and possibly other autoimmune diseases related to the interferon pathway," said Elizabeth H.Z. Thompson, Ph.D, executive vice president, research and development, Horizon. "Early studies indicate that HZN-7734 can deplete pDCs in blood and tissue thereby reducing Type 1 Interferon and the resulting inflammation, potentially addressing an unmet treatment need for patients with lupus. The enrollment of the first patient in this study represents an important milestone for these patients."

    About HZN-7734

    HZN-7734 is a fully human monoclonal antibody that targets ILT7 and, in early studies, has been shown to promote the destruction of plasmacytoid dendritic cells (pDCs). pDCs are thought to play a critical role in the pathogenesis of lupus and other autoimmune diseases through their capacity to produce rapid and robust quantities of Type 1 IFN as well as through IFN-independent mechanisms.

    About Systemic Lupus Erythematosus (SLE)

    SLE is marked by inflammation that can affect joints, skin and multiple organs. Symptoms can vary and may change over time, but skin rashes, swelling or pain in various parts of the body, extreme fatigue and low fevers are common. In some people, SLE can progress to more serious complications such as kidney damage, nervous system dysfunction and heart attack. The disease often occurs as periods of active disease, known as flares, alternating with periods where symptoms subside, known as remission.

    About Horizon

    Horizon is focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, please visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.

    Forward-Looking Statements

    This press release contains forward-looking statements, including, but not limited to, statements related to the potential benefits of HZN-7734; the expected scope, endpoints and timing of Horizon's Phase 2 clinical trial of HZN-7734 and other statements that are not historical facts. These forward-looking statements are based on Horizon's current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to clinical trials, including the fact that prior results may not predict future clinical trial outcomes; impacts of the COVID-19 pandemic and actions taken to slow its spread, including potential delays in clinical trials; regulatory obligations and oversight, including any changes in the legal and regulatory environment in which Horizon operates and those risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in Horizon's filings and reports with the SEC. Horizon undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information.

    References

    1. "What is systemic lupus erythematosus?" Lupus Foundation of America. https://www.lupus.org/resources/what-is-systemic-lupus-erythematosus-sle#. Accessed May 26, 2021.
    2. GfK Roper. (2012). Lupus Awareness Survey for the Lupus Foundation of America [Executive Summary Report]. Washington, DC.
    3. Lupus Facts and Statistics. Lupus Foundation of America. https://www.lupus.org/resources/lupus-facts-and-statistics#. Accessed June 14, 2021.
    4. Karnell JL, et al. Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in subjects with cutaneous lupus. Sci Trans Medicine. 2021;13(595): eabf8442.

     

    View Full Article Hide Full Article
View All Horizon Therapeutics Public Limited Company News